Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

NCT03821129 is registered in ClinicalTrials.gov with W.L.Gore & Associates as lead sponsor.

NCT NCT03821129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03821129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
Lead sponsor
W.L.Gore & Associates
Phase
Not applicable
Overall status
Recruiting
Start date
July 25, 2019
Completion date
October 31, 2031
Enrollment
636 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

pfo - patent foramen ovale, stroke